Esra Nur Ademoglu1, Suheyla Gorar2, Ayse Carlıoglu3, Havva Yazıcı4, Fatma Dilek Dellal2, Zehra Berberoglu2, Derya Akdeniz5, Sema Uysal6, Feridun Karakurt3. 1. Department of Endocrinology and Metabolism, Ankara Education and Research Hospital, Şükriye Mh, 06340, Sıhhıye, Ankara, Turkey. esranurademoglu@gmail.com. 2. Department of Endocrinology and Metabolism, Ankara Education and Research Hospital, Şükriye Mh, 06340, Sıhhıye, Ankara, Turkey. 3. Department of Endocrinology and Metabolism, Faculty of Medicine, Turgut Ozal University, Ankara, Turkey. 4. Department of Internal Medicine, Erzurum Education and Research Hospital, Erzurum, Turkey. 5. Department of Internal Medicine, Faculty of Medicine, Turgut Ozal University, Ankara, Turkey. 6. Department of Biochemistry, Faculty of Medicine, Turgut Ozal University, Ankara, Turkey.
Abstract
BACKGROUND: Nesfatin-1 is a recently discovered neuropeptide derived from its precursor nucleobindin-2 (NUCB2) and has been implicated in the regulation of feeding and energy metabolism. It is located in the brain and also produced at the periphery and present in the plasma. However, its pathophysiological role in humans remains unknown. Polycystic ovary syndrome (PCOS) is commonly presented with obesity, insulin resistance, hyperandrogenemia and hirsutism. AIM: To characterize serum nesfatin-1 levels in PCOS women and determine association of nesfatin-1 with metabolic parameters. MATERIALS AND METHODS: It is a cross-sectional study of 55 PCOS and 28 healthy women matched in age, in a university hospital setting. Anthropometric, hormonal, metabolic parameters and nesfatin-1 blood levels were determined. RESULTS: Nesfatin-1 levels were significantly higher in PCOS group compared with the controls 371.43 ± 2.50 versus 275.55 ± 1.74 pg/mL. Multivariate logistic regression analysis that contains: nesfatin-1, body mass index and homeostasis model assessment index revealed significant correlation of nesfatin-1 with the existence of PCOS (p < 0.05). CONCLUSIONS: Higher nesfatin-1 levels in PCOS women compared to control group may suggest a possibility that nesfatin-1 may play some role in the PCOS.
BACKGROUND:Nesfatin-1 is a recently discovered neuropeptide derived from its precursor nucleobindin-2 (NUCB2) and has been implicated in the regulation of feeding and energy metabolism. It is located in the brain and also produced at the periphery and present in the plasma. However, its pathophysiological role in humans remains unknown. Polycystic ovary syndrome (PCOS) is commonly presented with obesity, insulin resistance, hyperandrogenemia and hirsutism. AIM: To characterize serum nesfatin-1 levels in PCOS women and determine association of nesfatin-1 with metabolic parameters. MATERIALS AND METHODS: It is a cross-sectional study of 55 PCOS and 28 healthy women matched in age, in a university hospital setting. Anthropometric, hormonal, metabolic parameters and nesfatin-1 blood levels were determined. RESULTS:Nesfatin-1 levels were significantly higher in PCOS group compared with the controls 371.43 ± 2.50 versus 275.55 ± 1.74 pg/mL. Multivariate logistic regression analysis that contains: nesfatin-1, body mass index and homeostasis model assessment index revealed significant correlation of nesfatin-1 with the existence of PCOS (p < 0.05). CONCLUSIONS: Higher nesfatin-1 levels in PCOS women compared to control group may suggest a possibility that nesfatin-1 may play some role in the PCOS.
Authors: D Dewailly; H Gronier; E Poncelet; G Robin; M Leroy; P Pigny; A Duhamel; S Catteau-Jonard Journal: Hum Reprod Date: 2011-09-16 Impact factor: 6.918
Authors: Andreas Stengel; Miriam Goebel; Iskandar Yakubov; Lixin Wang; Derrick Witcher; Tamer Coskun; Yvette Taché; George Sachs; Nils W G Lambrecht Journal: Endocrinology Date: 2008-09-25 Impact factor: 4.736
Authors: G Cristina Brailoiu; Siok L Dun; Eugen Brailoiu; Saadet Inan; Jun Yang; Jaw Kang Chang; Nae J Dun Journal: Endocrinology Date: 2007-07-12 Impact factor: 4.736
Authors: M Karakose; K Demircan; E Tutal; T Demirci; M S Arslan; M Sahin; H T Celik; F Kazanci; J Karakaya; E Cakal; T Delibasi Journal: J Endocrinol Invest Date: 2016-05-04 Impact factor: 4.256